Currently Viewing:
ACC 2017
Marijuana Use Linked to High Risk of Heart Failure, Stroke
March 09, 2017
Ceramides Can Predict Who Will Develop Heart Disease, Study Finds
March 10, 2017
Erectile Dysfunction Drugs Are Safe After Heart Attacks
March 11, 2017
Currently Reading
When High Blood Pressure Means Lower Death Risk, but More Hospitalization
March 13, 2017
Bringing MACRA to Cardiologists, Ready or Not
March 17, 2017
Low-Dose Xarelto Beats Aspirin for Long-Term Prevention of Life-Threatening Blood Clots
March 18, 2017
Dr Robert P. Giugliano on the Results of the EBBINGHAUS Evolocumab Cognitive Study
March 18, 2017
Data Show It's Hard to Fill PCSK9 Prescriptions, Confirming Cardiologists' Complaints
March 19, 2017
Can SGLT2 Inhibitors Prevent Heart Failure in a Broad Population?
March 19, 2017
Dr Rob Nolan Discusses Findings From REACH Hypertension eCounseling Trial
March 19, 2017
Dr William Borden: Advice for Cardiologists on Adjusting to MACRA
March 19, 2017
Dr Janet Wright Outlines Goals and Roadblocks of Million Hearts Initiative
March 20, 2017
Charting the Path to Health Equity: Steps for Providers
March 20, 2017
Dr Jim McDermott Discusses Objectives and Outcomes of CVD-REAL Trial
March 20, 2017
Dr Seth J. Baum on the Patient's Role in Getting PCSK9 Inhibitors Approved by Payers
March 20, 2017
Dr Robert P. Giugliano Discusses the Significance of the FOURIER and EBBINGHAUS Trials
April 06, 2017
Dr Janet Wright Discusses How Million Hearts Will Leverage Partnerships for Success
April 06, 2017
Dr Seth J. Baum Discusses Payers' Reluctance to Approve Coverage of PCSK9 Inhibitors
April 07, 2017
Dr Rob Nolan on the Future Directions of eCounseling Research
April 14, 2017
Dr Janet Wright on Cardiologists' Role in Public Health and Prevention Efforts
April 15, 2017
Dr William Borden Discusses MACRA Requirements From a Cardiologist's Perspective
May 08, 2017
Dr Seth J. Baum on the Patient's Role in Getting PCSK9 Inhibitors Approved by Payers
May 10, 2017
Dr Rob Nolan Explains Behavioral Principles Behind eCounseling Hypertension Program
May 15, 2017
Dr Rob Nolan Discusses Behavioral Foundations of eCounseling Programs
June 10, 2017

When High Blood Pressure Means Lower Death Risk, but More Hospitalization

Mary Caffrey
The study's lead author said the findings may show something similar to the "obesity paradox," where high-risk patients fare better than expected due to frequent follow-up by physicians.
A study being presented this week at the American College of Cardiology (ACC) 66th Scientific Session finds that for some patients, having high systolic blood pressure does not lead to a higher risk of death, even though there are important implications for managed care.

The study, involving the Gulf-CARE registry and funded by Servier, a French pharmaceutical company, examined health records of 2492 patients with type 2 diabetes (T2D) who were among 5005 hospitalized with acute heart failure in 7 Middle Eastern countries: Oman, Saudia Arabia, Yemen, Kuwait, Qatar, Bahrain, and United Arab Emirates.

Results show that patients with both T2D and acute heart failure had a lower risk of death—but a higher risk of heart-related hospitalization—if they had high systolic blood pressure when discharged from the hospital, when compared with those with normal blood pressure. Although this study does not involve US health records, it’s worth looking at the results given that Medicare and many commercial health plans in the United States closely scrutinize 30-day readmission rates, and hospitals can face penalties for failing to meet targets in this area.

A statement from the ACC said this was the first study to examine blood pressure and health outcomes among people with T2D and among those with heart failure. Those with systolic blood pressure above 150 mmHg were 45% less likely to die, but 47% more likely to be hospitalized for heart failure during a 12-month follow up period. A normal systolic blood pressure reading should be lower than 140 mmHg in patients with diabetes, and lower than 130 mmHg in everyone else.

However, patients suffering from both conditions may have a “distinct pathophysiology of the heart and may benefit from different guidelines,” said lead study author Charbel Abi Khalil, MD, PhD, assistant professor of medicine and genetic medicine at Weill Cornell Medicine and cardiology consultant at the heart hospital Hamad Medical Corporation in Doha, Qatar.

Abi Khalil speculated that the results may point to a “blood pressure paradox,” which could be similar to a phenomenon known as the “obesity paradox,” in which patients with obesity and T2D have better survival that those without. Because this is an association and not a cause and effect, it’s been speculated that this may occur because these patients are followed more closely by physicians, and the same may be true of patients with heart failure and diabetes. The frequent follow-ups may suggest more care by cardiologists and diabetes specialists, along with early diagnosis of other health problems.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up